DOCS Stock Recent News

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal first quarter ended June 30, 2025 after market close on August 7, 2025. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before.

Doximity (DOCS) concluded the recent trading session at $61.55, signifying a +2.24% move from its prior day's close.

Dr Martens PLC (LSE:DOCS) said trading since the start of the financial year has been in line with expectations, with guidance for its current financial year unchanged and profit expected to be weighted to the second half The FTSE 250-listed footwear manufacturer and retailer reported a "positive" performance for its direct-to-consumer business in the Americas, particularly in its shops and full-price sales, though the UK continued to see "a challenging trading backdrop". In Europe, the Middle East and Africa, trading was mixed, while the Asia Pacific region delivered strong growth, led by South Korea.

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential legal claims on behalf of Doximity, Inc. (NYSE: DOCS) shareholders, concerning alleged misconduct by certain officers and directors that may have harmed the company and its investors.

I have a price target of $85 for Doximity by summer 2026. There is lots to be bullish about. Doximity's fundamentals are strong: zero debt, a large cash cushion, and robust free cash flow generation support my bullish outlook. Despite unimpressive 11% revenue growth guidance, DOCS surpasses the Rule of 40 with a Rule of 58, justifying a premium valuation.

Doximity (DOCS) concluded the recent trading session at $61.09, signifying a +1.13% move from its prior day's close.

DOCS sharpens its enterprise focus with AI and workflow tools, signaling a deeper pivot beyond pharma marketing roots.

DOCS is leaning on AI tools like Doximity GPT to fuel growth after a strong FY25, but monetization remains early-stage.

DOCS and IRTC are redefining digital health with AI, but only one is winning big with investors in 2025's market surge.

I rate Doximity a 'Buy' with a $62 fair value, citing its dominant network among U.S. healthcare professionals and robust growth trajectory. Doximity's strong pharma marketing business, workflow solutions, and AI-driven hiring tools underpin its competitive advantage and long-term expansion potential. The company's debt-free balance sheet, high free cash flow, and substantial share repurchases support its financial health and margin expansion outlook.